Expressions of serum factors in the breast ductal carcinoma in situ and invasive ductal carcinoma and their impact on prognosis
Objective To explore the difference of expression of interleukin(IL-6),IL-8,IL-22,squamous cell carcinoma antigen(SCC-Ag)and cytokeratin-19-fragment(CYFRA21-1)in peripheral blood in ductal carcinoma in situ(DCIS)and invasive ductal carcinoma(IDC)and its influence on prognosis.Methods 126 DCIS patients were selected as the DCIS group,153 IDC patients as the IDC group,and another 134 healthy individuals were selected as the control group.Patients in the IDC group were categorized into group Ⅰ(mild IDC patients with TNM stage Ⅰ+Ⅱ,62 cases)and group Ⅱ(severe IDC patients with TNM stage Ⅲ+Ⅳ,91 cases)according to TNM staging.Patients in the DCIS group and IDC group were treated with radiotherapy or radiotherapy combined with chemotherapy.Serum levels of IL-6,IL-8 and IL-22 were determined by enzyme linked immunosorbent assay,SCC-Ag was determined by chemiluminescence microparticle immunoassay,and CYFRA21-1 was determined by chemiluminescent immunoassay.Comparison was made on clinical characteristics of DCIS and IDC patients,serum IL-6,IL-8 and IL-22 levels in each group,serum IL-6,IL-8 and IL-22 levels in each group of patients with different therapeutic effects,SCC-Ag and CYFRA21-1 levels in each group.The survival of patients was analyzed.Results Compared with control group,the serum levels of IL-6,IL-8 and IL-22 in DCIS group,IDC-Ⅰ group and Ⅱ group were significantly increased(P<0.05).Compared with DCIS group,the serum levels of IL-6,IL-8 and IL-22 in IDC-Ⅰ group and Ⅱ group were significantly increased(P<0.05).Compared with IDC-Ⅰ group,the serum levels of IL-6,IL-8 and IL-22 in IDC-Ⅱ group were significantly increased(P<0.05).The serum IL-6,IL-8 and IL-22 of patients with complete response(CR)+partial response(PR)in DCIS group,IDC-Ⅰ group and IDC-Ⅱ group were significantly decreased compared with stable disease(SD)+progressive disease(PD)patients(P<0.05).There were 5 cases of postoperative recurrence in DCIS group and 16 cases in IDC group,respectively,and the levels of SCC-Ag and CYFRA21-1 in DCIS group and IDC group were significantly higher than those in control group(P<0.05).The SCC-Ag positivity rate was 60.0%(3/5)and CYFRA21-1 positivity rate was 80.0%(4/5)in patients with postoperative recurrence in the DCIS group;the SCC-Ag positivity rate in the IDC group was 62.5%(10/16),and the CYFRA21-1 positivity rate was 68.8%(11/16)in patients with postoperative recurrence.The 1-,2-,and 3-year survival rates of 279 breast cancer patients were 44.8%(125/279),18.6%(52/279),and 13.3%(37/279),respectively.The median survival of SCC-Ag-negative patients was 25 months,while that of SCC-Ag-positive patients was 16 months.The median survival time of SCC-Ag-negative patients was longer than that of SCC-Ag-positive patients.The median survival of CYFRA21-1-negative patients was 14 months,while that of CyFRA21-1-positive patients was 9 months.The median survival of CyFRA21-negative patients was longer than that of CyFRA21-1-positive patients.Conclusion Serum IL-6,IL-8,IL-22,SCC-Ag,and CYFRA 21-1 were considered as potential markers in the metastasis and prognosis of breast cancer.
Breast ductal carcinoma in situBreast invasive ductal carcinomaSerum factorsExpressionPrognosis
万方数据
维普
